Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check2 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check9 days agoChange DetectedThe site revision label in the footer changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedThe study page now displays a 403 Forbidden error rather than the study details, indicating access is blocked or restricted. This prevents viewing the trial information while the underlying data remains unchanged.SummaryDifference20%

- Check52 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, signaling a new site build or update for the study details page.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page’s revision label was updated to v3.6.5, indicating a new maintenance release of the study page. No study details or content appear to have changed as part of this update.SummaryDifference0.0%

- Check87 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4. This represents a minor update to the page's revision history rather than changes to the study details or user-facing content.SummaryDifference0.0%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.